All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Antimicrobial resistance (AMR) is the ability of bacteria, parasites, viruses and fungi to grow and spread in the presence of antimicrobial medicines that are normally active against them. AMR occurs via a range of resistance mechanisms, such as a modified antimicrobial target, enzymatic hydrolysis/degradation, efflux and impermeability. This resistance is mediated by diverse resistance genes that evolve as a result of antimicrobial selection pressure exerted by the appropriate and/or inappropriate use of antimicrobial medicines, and is aggravated by the void of new antimicrobial agents in the current therapeutic pipeline \[[@pone.0189621.ref001], [@pone.0189621.ref002]\]. AMR increases health-care costs, length of stay in hospitals, morbidity and mortality in both developed and developing countries \[[@pone.0189621.ref003]\]. A recent report estimated that 10 million deaths will be attributed to AMR by 2050, and 100 trillion USD of the world's economic outputs will be lost if substantive efforts are not made to contain this threat \[[@pone.0189621.ref001], [@pone.0189621.ref004], [@pone.0189621.ref005]\].

The World Health Organization (WHO) published the first global surveillance report on antibiotic resistance (ABR) in 2014 to show the clinical impact of resistant bacteria in WHO regions across the world. This reported shown that five out of the six WHO regions had more than 50% resistance to third generation cephalosporins and fluoroquinolones in *Escherichia coli* and methicillin resistance in *Staphylococcus aureus* in hospital settings. Similarly, more than 50% resistance to third generation cephalosporins and carbapenems was reported in *Klebsiella pneumoniae*. The report attributed 45% of deaths in both Africa and South-East Asia to multi-drug resistant (MDR) bacteria. It further revealed that *K*. *pneumonia*e resistant to third generation cephalosporins was associated with elevated deaths in Africa (77%), the Eastern Mediterranean region (50%), South East Asia (81%) and Western Pacific region (72%) \[[@pone.0189621.ref002]\].

Several resistant bacteria have been increasingly involved in infectious diseases in humans, specifically, *Enterococcus spp*, *S*. *aureus*, *K*. *pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter spp*. They are collectively termed ESKAPE and recently gained further global attention by being listed by the WHO as priority antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics \[[@pone.0189621.ref005]\]. The particularity of these bacteria is their ability to develop high level resistance to multiple drugs, thereby limiting therapeutic options and increasing morbidity and mortality. Numerous studies have confirmed that ESKAPE bacteria and their resistant clones, are actively transmitted in hospitals and communities in both developed and developing countries. The threat posed by these resistant bacteria is however exacerbated in developing countries due to sub-optimal hygiene conditions, poor infection, prevention and control measures, lack of surveillance and the dearth antimicrobial stewardship programs \[[@pone.0189621.ref006], [@pone.0189621.ref007]\]. Reports have shown high isolation rates of methicillin resistant *S*. *aureus* (MRSA) in healthcare settings in Cameroon (72%), South Africa (52%), Ethiopia (42.8%), Nigeria (29.6%), Kenya (27.7%), Ivory Cost (16.8%) and Morocco (14.4%) \[[@pone.0189621.ref002], [@pone.0189621.ref008]--[@pone.0189621.ref010]\]. In 2008, the prevalence of nosocomial acquired and MDR infections due to Enterobacteriaceae isolated from blood cultures were 57.1% and 15.4% respectively, in South Africa \[[@pone.0189621.ref011]\]. Likewise, rapid increases in the rates of infections due to carbapenemase-producing *K*. *pneumonia*, metallo-beta-lactamase-producing *A*. *baumannii* (MBL-AB), metallo-beta-lactamase-producing *P*. *aeruginosa* (MBL-PA), and extended-spectrum beta-lactamase (ESBL) producing *Enterobacter spp*. have been reported across the world \[[@pone.0189621.ref012]--[@pone.0189621.ref014]\]. In Saudi Arabia, the rate of *P*. *aeruginosa* producing carbapenemase was 33%, of which 27% were MBL-producers \[[@pone.0189621.ref015]\], while in India, a 22.4% prevalence of *P*. *aeruginosa* producing MBLs was reported in tertiary care hospitals \[[@pone.0189621.ref016]\].

MDR-ESKAPE bacteria have been reported in hospital acquired infections (HAI), particularly in intensive care units (ICUs) where immune-compromised patients suffering from some non-communicable diseases (NCDs) including diabetes, cancers, chronic lung, cardiovascular and kidney diseases were highly affected \[[@pone.0189621.ref006], [@pone.0189621.ref017]--[@pone.0189621.ref022]\]. The emergence and spread of these highly resistant bacteria in hospital care settings could thus have negative health repercussions and be an obstacle for the treatment of infections of patients with these NCDs \[[@pone.0189621.ref018], [@pone.0189621.ref023]\].

Despite the evidenced threat posed by ABR, information on its clinical and economic impact is limited in developing countries, and thus impede appropriate interventions for its containment \[[@pone.0189621.ref024], [@pone.0189621.ref025]\]. Heightened awareness of policy-makers, health care workers, and the general population about the risks associated with ABR is essential to preserve antibiotics for future generations \[[@pone.0189621.ref026], [@pone.0189621.ref027]\]. Hence, the aim of this study was to analyze the published literature on the clinical and economic impact of ABR in developing countries, in order to inform containment strategies such as antimicrobial stewardship programs and infection prevention and control measures in these nations.

Methods {#sec006}
=======

The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed \[[@pone.0189621.ref028], [@pone.0189621.ref029]\].

Ethical consideration {#sec007}
---------------------

This systematic review and meta-analysis was based on published reports, and was therefore exempt from ethical approval.

Systematic review of the literature {#sec008}
-----------------------------------

A systematic search was carried out independently by RF and LF, in Medline via PubMed and Web of Sciences from January 2000 to December 09, 2016, using a combination of boolean operators (AND/OR), Medical Subject Heading (MeSH) and pre-defined keywords. Only published after 2000 were considered to ensure that the analysis focuses on contextual literature that depict current resistance patterns, infection rates, prevention measures, and clinical practice guidelines. Peer-reviewed papers in English and French on the clinical and/or economic impacts of ABR in developing countries were retrieved and independently evaluated for eligibility by RF and LF based on titles and abstracts ([Table 1](#pone.0189621.t001){ref-type="table"}). Thereafter, the full-texts of eligible papers were assessed according to pre-defined inclusion and exclusion criteria ([Table 1](#pone.0189621.t001){ref-type="table"}), with inconsistencies and disagreements being resolved by consensus. Efforts were made to contact the authors when data was missing and full-texts could not be retrieved, and a hand search was conducted in the reference list of all selected papers.

10.1371/journal.pone.0189621.t001

###### Eligibility criteria.

![](pone.0189621.t001){#pone.0189621.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------
  ***Inclusion criteria***

  \- Original research\
  - Minimum of 20 patients\
  - Studies conducted in developing countries as defined by World Bank criteria\
  - Report on association between resistant bacteria and clinical outcome and/or financial impact\
  - Antimicrobial susceptibility testing done by either disk diffusion, broth micro-dilution, agar dilution, E-test or VITEK using\
  - CLSI/EUCAST/SFM guidelines\
  - Papers published in French and English\
  - Studies published from January 1, 2000

  ***Exclusion criteria***

  \- Reports of antibiotic resistance unrelated to clinical outcome nor economic impact\
  - Reports on parasites, viruses and fungi\
  - Reports on treatment comparisons\
  - Studies conducted in developed countries as defined by World Bank criteria\
  - Reports published in languages other than French and English\
  - Antibiotic resistance in wildlife, companion and aquatic animals\
  - Grey literature, conference abstracts, reviews, meta-analysis, letters to editor, correspondence, editorials, comments and case reports.\
  - Studies published before January 1, 2000
  ---------------------------------------------------------------------------------------------------------------------------------------------

Screening and data extraction process {#sec009}
-------------------------------------

Papers were managed using EndNote (version X7.7.1, Thomson Reuters) and the data from eligible papers was abstracted independently by two authors (RF and LF) using a standardized data extraction spreadsheet in Excel^®^ (Microsoft^®^ Office Excel 2016). Relevant data from papers included countries, WHO regions, World Bank classification, publication year, type of study, participant characteristics (number of participant, diseases, age), hospital' ward, bacteria, follow-up period, length of stay in hospital, mortality related to resistant bacteria, and, costs as described in [Table 2](#pone.0189621.t002){ref-type="table"}.

10.1371/journal.pone.0189621.t002

###### Description of eligible papers included in the systematic review.

![](pone.0189621.t002){#pone.0189621.t002g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                                                              Year   Type of study                                                    Study population                 Infection type                           Hospital' ward                                        Bacteria                                Sample size\   Length of stay[^2^](#t002fn003){ref-type="table-fn"}\   Mortality[^3^](#t002fn004){ref-type="table-fn"}\   References                          
                                                                                                                                                                                                                                                                                                                       cases/\        (%)                                                     n/N (%)                                                                                
                                                                                                                                                                                                                                                                                                                       controls                                                                                                                                                      
  -------------------------------------------------------------------- ------ ---------------------------------------------------------------- -------------------------------- ---------------------------------------- ----------------------------------------------------- --------------------------------------- -------------- ------------------------------------------------------- -------------------------------------------------- ----------------- ----------------- ----------------------------
  **STUDIES REPORTING IMPACT OF ABR ON THE MORBIDITY ONLY**                                                                                                                                                                                                                                                                                                                                                                                                                          

  Turkey                                                               2015   Retrospective cohort                                             NR                               Nosocomial BSI                           ICU                                                   *A*. *baumannii*                        41/45          25.49 days (%NR)                                        22.80 days (%NR)                                   NR                NR                \[[@pone.0189621.ref003]\]

  Turkey                                                               2008   Prospective case---control                                       Adults\>16 years old             Nosocomial Infections                    ICU and others                                        *A*. *baumannii*                        66/57          20.8 days (65.2%)                                       15.4 days (40.4%)                                  NR                NR                \[[@pone.0189621.ref030]\]

  **STUDIES REPORTING IMPACT OF ABR ON THE MORTALITY ONLY**                                                                                                                                                                                                                                                                                                                                                                                                                          

  Brazil                                                               2009   Retrospective case-control                                       Adults \>14 years old            Nosocomial infections                    Medical-surgical ICU                                  *P*. *aeruginosa*                       63/182         NR                                                      NR                                                 31/63 (49%)       61/182 (33%)      \[[@pone.0189621.ref031]\]

  Brazil                                                               2009   Case-control                                                     Adults \> 18 years old           BSI                                      NR                                                    *E*. *coli* and *K*. *pneumoniae*       30/64          NR                                                      NR                                                 7/30\             12/64\            \[[@pone.0189621.ref032]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                 (23.3%)           (18.8%)           

  China                                                                2004   Case-control and Retrospective cohort                            All ages                         MDR-HAI                                  Various wards[^1^](#t002fn002){ref-type="table-fn"}   *P*. *aeruginosa*                       44/68          NR                                                      NR                                                 24/44 (54.5%)     11/68 (16.2%)     \[[@pone.0189621.ref033]\]

  China                                                                2012   Retrospective                                                    Children \< 15 years old         Pneumonia                                Pediatric ICU                                         *A*. *baumannii*                        115/45         NR                                                      NR                                                 21/115 (18.26%)   2/45 (4.44%)      \[[@pone.0189621.ref034]\]

  China                                                                2015   Retrospective Case-Control                                       NR                               MRSA infections                          Various                                               *S*. *aureus*                           57/116         NR                                                      NR                                                 12/57 (21%)       9/116\            \[[@pone.0189621.ref035]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (8%)              

  Colombia                                                             2014   Case-Control                                                     All ages                         CR-KP Infection                          ICU                                                   *K*. *pneumoniae*                       61/122         NR                                                      NR                                                 31/61 (50.8%)     25/122 (20.4%)    \[[@pone.0189621.ref036]\]

  India                                                                2014   NR                                                               Neonates                         BSI                                      Neonatal ICU                                          *A*. *baumannii*                        33/32          NR                                                      NR                                                 9/33 (27.3%)      3/32\             \[[@pone.0189621.ref037]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (9.4%)            

  Malaysia                                                             2009   Case-control                                                     NR                               Nosocomial AB BSI                        NR                                                    *A*. *baumannii*                        53/56          NR                                                      NR                                                 25/53 (47.2%)     14/56 (25%)       \[[@pone.0189621.ref038]\]

  Malaysia                                                             2011   Cross-sectional descriptive and case-control                     NR                               IR-*A*. *baumannii* BSI                  NR                                                    *A*. *baumannii*                        15/41          NR                                                      NR                                                 9/15 (64.3%)      15/41 (40.5%)     \[[@pone.0189621.ref039]\]

  Mexico                                                               2000   Case-control                                                     Children                         Pneumoniae                               NR                                                    *S*. *pneumoniae*                       25/24          NR                                                      NR                                                 11/25\            7/24\             \[[@pone.0189621.ref040]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                 (44%)             (29%)             

  Thailand                                                             2011   Case-control                                                     Adults \>15 years old            MDR-*A*. *baumannii* bacteremia          In and out-patient departments                        *A*. *baumannii*                        24/25          NR                                                      NR                                                 22/24 (91.7%)     12/25 (48%)       \[[@pone.0189621.ref041]\]

  Thailand                                                             2012   Case-control                                                     Adults \>15 years old            ESBL-producing bacteria in\              In and out-patient departments                        *E*. *coli*                             32/113         NR                                                      NR                                                 9/32 (29%)        13/113 (11.5%)    \[[@pone.0189621.ref042]\]
                                                                                                                                                                                septicemia                                                                                                                                                                                                                                                                                           

  Thailand                                                             2015   Case-control                                                     Adults\>18 years old             HAI                                      ICU and general wards                                 *A*. *baumannii*                        139/132        NR                                                      NR                                                 79/139\           3/132\            \[[@pone.0189621.ref043]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                 (57%)             (2%)              

  Thailand                                                             2015   Retrospective cohort                                             Adults                           Ventilator Associated Pneumoniae         ICU                                                   *A*. *baumannii*                        220/33         NR                                                      NR                                                 125/220 (56.8%)   7/33\             \[[@pone.0189621.ref044]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (21.2%)           

  **STUDIES REPORTING IMPACT OF ABR ON THE MORBIDITY AND MORTALITY**                                                                                                                                                                                                                                                                                                                                                                                                                 

  Brazil                                                               2015   Case-control                                                     Cancer children \<18 years old   MDR-GNB Infection                        Oncology pediatric ICU                                Gram Negative Bacteria                  47/54          8 days (63.8%)                                          2 days (37%)                                       12/47 (25.5%)     9/54 (16.7%)      \[[@pone.0189621.ref017]\]

  Brazil                                                               2006   Retrospective cohort                                             \>1-year-old                     BSI                                      Various wards[^1^](#t002fn002){ref-type="table-fn"}   *S*. *aureus*                           61/50          \>10 days (65.9%)                                       \>10 days (34.1%)                                  33/61 (54.9%)     12/50 (24.7%)     \[[@pone.0189621.ref045]\]

  Brazil                                                               2006   Retrospective cohort                                             All ages                         BSI                                      Various wards[^1^](#t002fn002){ref-type="table-fn"}   *K*. *pneumoniae*                       56/52          \>10 days\                                              \>10 days (43.8%)                                  18/56 (69.2%)     8/52\             \[[@pone.0189621.ref046]\]
                                                                                                                                                                                                                                                                                                                                      (56.2%)                                                                                                                      (30.8%)           

  Brazil                                                               2008   Case-control                                                     Adults                           VAP                                      ICU                                                   *S*. *aureus*                           29/32          \>8 days (89.7%)                                        \>8 days (90.6%)                                   11/29 (37.9%)     8/32\             \[[@pone.0189621.ref047]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (25%)             

  Brazil                                                               2012   Case-control                                                     Adults \> 18 years old           Bacteremia                               ICU                                                   *P*. *aeruginosa*                       29/48          43 days (NR)                                            43.1 days (NR)                                     13/29 (44.8%)     26/48\            \[[@pone.0189621.ref022]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (54.2%)           

  China                                                                2012   Retrospective cohort                                             \> 1 year old                    BSI                                      Various wards[^1^](#t002fn002){ref-type="table-fn"}   *S*. *aureus*                           75/43          55.3 days (NR)                                          38.7 days (NR)                                     25/75 (33.3%)     8/43 (18.6%)      \[[@pone.0189621.ref048]\]

  China                                                                2015   Retrospective                                                    Geriatric inpatients             Bacteremia                               Various wards[^1^](#t002fn002){ref-type="table-fn"}   *A*. *baumannii*                        39/86          36.7 days\                                              36.1 days (NR)                                     31/39\            38/86\            \[[@pone.0189621.ref049]\]
                                                                                                                                                                                                                                                                                                                                      (NR)                                                                                                       (79.5%)           (44.2%)           

  China                                                                2015   Retrospective case-control                                       NR                               Enterococci infections                   Various wards[^1^](#t002fn002){ref-type="table-fn"}   *Enterococci*                           44/176         37 days (NR)                                            17 days (NR)                                       3/44 (6.8%)       3/176 (1.7%)      \[[@pone.0189621.ref050]\]

  Colombia                                                             2014   Prospective cohort                                               Adult                            CR-*A*. *baumannii* Infections           ICU                                                   *A*. *baumannii*                        104/61         19 days (NR)                                            16.2 days (NR)                                     42/104\           13/61 (21%)       \[[@pone.0189621.ref051]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                 (40%)                               

  India                                                                2014   Observational                                                    Adults                           Septicemia                               Various wards                                         GNB and GPB                             133/87         14 days (NR)                                            11 days (NR)                                       16/133 (12%)      2/87\             \[[@pone.0189621.ref052]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (2%)              

  Jordan                                                               2015   Matched case-control                                             Cancer patients                  Nosocomial *A*. *baumannii* infections   Medical-surgical ICU                                  *A*. *baumannii*                        161/262        12 days\                                                3 days\                                            118/161 (73.3%)   142/232 (61.2%)   \[[@pone.0189621.ref053]\]
                                                                                                                                                                                                                                                                                                                                      (NR)                                                    (NR)                                                                                   

  Palestine                                                            2009   Prospective case---control                                       Neonates                         Nosocomial septicemia\                   Neonatal ICU                                          *A*. *baumannii*                        40/100         20 days\                                                20 days\                                           15/40 (37.5%)     12/100 (13.2%)    \[[@pone.0189621.ref054]\]
                                                                                                                                                                                                                                                                                                                                      (62.5%)                                                 (35%)                                                                                  

  Senegal                                                              2016   Classic retrospective cohort and retrospective parallel cohort   All ages                         ESBL- producing Enterobacteriaceae       Various wards[^1^](#t002fn002){ref-type="table-fn"}   *K*. *pneumoniae*\                      110/76         22.6 days\                                              14 days\                                           52/110 (47.3%)    17/76\            \[[@pone.0189621.ref055]\]
                                                                                                                                                                                                                                                                               *Enterobacter*\                                        (NR)                                                    (NR)                                                                 (22.4%)           
                                                                                                                                                                                                                                                                               *E*. *coli*                                                                                                                                                                                           

  Thailand                                                             2007   Prospective case---control                                       Adults                           HAI                                      Various wards[^1^](#t002fn002){ref-type="table-fn"}   *E*. *coli* and *K*. *pneumoniae*       74/74          22.5 days\                                              17.5 days\                                         26/74 (35.1%)     12/74 (16.2%)     \[[@pone.0189621.ref056]\]
                                                                                                                                                                                                                                                                                                                                      (NR)                                                    (NR)                                                                                   

  Thailand                                                             2008   Cohort                                                           Adults                           Community-onset BSI                      Various wards[^1^](#t002fn002){ref-type="table-fn"}   *E*. *coli* and *K*. *pneumoniae*       36/108         8 days (NR)                                             6 days (NR)                                        13/36 (36%)       16/108 (15%)      \[[@pone.0189621.ref057]\]

  Thailand                                                             2014   Retrospective cohort                                             Adults\>18 years old             HAI                                      Various wards[^1^](#t002fn002){ref-type="table-fn"}   *A*. *nosocomialis* and *A*. *pittii*   25/58          9 days (NR)                                             4 days (NR)                                        3/25 (12%)        20/58 (35%)       \[[@pone.0189621.ref058]\]

  Thailand                                                             2009   Retrospective cohort                                             Adult\> 15 years old             Nosocomial BSI                           Various wards[^1^](#t002fn002){ref-type="table-fn"}   *A*. *baumannii*                        67/131         37 days (NR)                                            27 days (NR)                                       35/67 (52.2%)     26/131 (19.9%)    \[[@pone.0189621.ref059]\]

  Thailand                                                             2006   Cross-sectional                                                  All ages                         Community-acquired pneumoniae            NR                                                    *S*. *pneumoniae*                       22/42          12.2 days (NR)                                          15.5 days (NR)                                     2/22\             4/42\             \[[@pone.0189621.ref060]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                 (9.1%)            (9.5%)            

  Thailand                                                             2009   Case-control                                                     Adult\>18 years old              Nosocomial BSI                           Various wards[^1^](#t002fn002){ref-type="table-fn"}   *E*. *coli* and *K*. *pneumoniae*       51/94          26 days (NR)                                            16 days (NR)                                       26/51 (51.0%)     28/94 (29.8%)     \[[@pone.0189621.ref061]\]

  Thailand                                                             2013   Retrospective Case-control                                       Neonates                         CR- *A*. *baumannii* Bacteremia          Neonatal ICU                                          *A*. *baumannii*                        14/44          34 days\                                                24.5 days (NR)                                     6/14 (42.9%)      3/44\             \[[@pone.0189621.ref062]\]
                                                                                                                                                                                                                                                                                                                                      (NR)                                                                                                                         (5.9%)            

  Thailand                                                             2016   Retrospective Case-control                                       Neonates                         VAP                                      Neonatal ICU                                          *A*. *baumannii*                        63/25          51 days (NR)                                            41 days\                                           10/63\            0/25\             \[[@pone.0189621.ref019]\]
                                                                                                                                                                                                                                                                                                                                                                                              (NR)                                               (15.9%)           (0%)              

  Turkey                                                               2015   Observational retrospective cohort                               All ages                         HAI                                      ICU                                                   *K*. *pneumoniae*                       47/51          19 days (37.3%)                                         11 days (29.94%)                                   21/47\            26/51 (51%)       \[[@pone.0189621.ref063]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                 (44.7%)                             

  Turkey                                                               2000   Retrospective                                                    Adults                           Bacteremia                               ICU                                                   *S*. *aureus*                           46/55          50.3 days (NR)                                          32.7 days (NR)                                     15/46\            7/55\             \[[@pone.0189621.ref021]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                 (32.6%)           (12.7%)           

  Turkey                                                               2015   NR                                                               NR                               Nosocomial infections                    Emergency ICU and Pediatric ICU                       *P*. *aeruginosa*                       32/8           20.58 days (NR)                                         6.33 days (NR)                                     14/32 (43.8%)     2/8 (25%)         \[[@pone.0189621.ref064]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOS: Length of stay; NR: Not reported; BSI: Bloodstream infection, HAI: Hospital-acquired infection, VAP: Ventilator-Associated Pneumoniae; CR: Carbapenem-resistant; GNB: Gram negative bacteria; GPB: Gram positive bacteria

1 various wards

2 LOS attributed to the specific bacteria responsible of the infections

3: Overall mortality attributed to the specific bacteria responsible of the infections, ICU: Intensive Care Unit.

Statistical analysis {#sec010}
--------------------

Meta-analyses were undertaken using Comprehensive Meta-analysis software (Biostat, Inc., New Jersey, USA) version 3 for Windows, to determine overall mortality risk associated with resistance. Sub-group analyses for mortality were conducted for the data by WHO region, World Bank classification, countries, group of bacteria, and bacterial species where there were three or more studies that could be combined. Forest plots were performed to assess the significance of the results and generated using 95% confidence intervals (CIs). Analyses were undertaken across sub-groups for the selected outcome and the results presented as odds ratios. Studies were weighted in favor of those with narrower confidence intervals (more precise results), and the random-effects method was used to provide more confident data considering heterogeneity within and between reports. The *I-square (I*^*2*^*)* statistic with cut-off values of 25, 50 and 75% was used to assess low, moderate and high heterogeneity respectively, and a *p-*value of \<0.05 was considered statistically significant. Publication bias was evaluated using the funnel plot and statistical egger's test.

Quality assessment {#sec011}
------------------

Quality assessment was performed independently by RF and LF using the Newcastle-Ottawa quality assessment scale (NOS) for each study included in the systematic review and meta-analysis \[[@pone.0189621.ref065]\]. NOS assesses methodological quality, based on three-dimensional criteria and included (i) selected population, (ii) comparability of groups, and (iii) outcome/exposure of interest. Studies were scored using a scale with a possible maximum of eight points where a score ≥ 6 indicated high-quality studies, a score between 3--6 as moderate and a score ≤ 3 as low quality.

Results {#sec012}
=======

Literature search and study selection {#sec013}
-------------------------------------

The systematic search conducted in the two electronic databases generated 27 033 papers. A total of 24 057 papers were screened for probable inclusion according to titles and abstracts after de-duplication. Of these, the full texts of 92 eligible papers were fully evaluated based on predefined inclusion and exclusion criteria. One article was added following a hand-search in the reference lists of included papers. Forty studies were finally eligible for the qualitative and quantitative analysis ([Fig 1](#pone.0189621.g001){ref-type="fig"}), of which 18 were of high quality, while 15 and seven were moderate and low quality respectively.

![Prisma Flow-chart illustrating the study selection process.](pone.0189621.g001){#pone.0189621.g001}

Description and characteristics of studies included in systematic review {#sec014}
------------------------------------------------------------------------

The majority of data analyzed were obtained from single center studies conducted in 11 countries. Thirty percent (n = 12) of the observational studies on ABR were conducted in hospitals and communities in Thailand, the rest were performed in 10 different-countries namely Brazil (n = 7; 17.5%), China (n = 6; 15%), Turkey (n = 5; 12.5%), Colombia (n = 2; 5%), Malaysia (n = 2; 5%), India (n = 2; 5%), Mexico (n = 1; 2.5%), Jordan (n = 1; 2.5%), Palestine (n = 1; 2.5%), and Senegal (n = 1; 2.5%) ([Table 2](#pone.0189621.t002){ref-type="table"} and [Fig 2](#pone.0189621.g002){ref-type="fig"}).

![Graphical representation of AMR in developing countries included in the study.](pone.0189621.g002){#pone.0189621.g002}

Fourteen studies investigated the impact of ABR on mortality, two reported its impact on morbidity only ([Table 2](#pone.0189621.t002){ref-type="table"}) while 24 considered both morbidity and mortality concomitantly. Eight studies reported on the economic consequences of ABR ([Table 3](#pone.0189621.t003){ref-type="table"}). *A*. *baumannii* (n = 14; 35%), *K*. *pneumoniae* (n = 6; 15%), *S*. *aureus* (n = 5; 12.5%), *P*. *aeruginosa* (n = 4; 10%) represented the main pathogens reported with ICUs being the principal hospital ward concerned (Tables [2](#pone.0189621.t002){ref-type="table"} and [3](#pone.0189621.t003){ref-type="table"}).

10.1371/journal.pone.0189621.t003

###### Studies describing mortality rate associated with resistant and MDR ESKAPE bacteria.

![](pone.0189621.t003){#pone.0189621.t003g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                            Hospital Wards       Bacteria                                                      Mortality rate   P-value   References
  ------------------------------------------------------------------ -------------------- ------------------------------------------------------------- ---------------- --------- ----------------------------
  Al Jarousha et al. (2009)                                          Neonatal ICU         MDR-*A*. *baumannii* (15/40)                                  37.5%            0.001     \[[@pone.0189621.ref054]\]

  Susceptible *A*. *baumannii* (12/100)                              12%                                                                                                           

  Anunnatsiri et al. (2011)\                                         ICU                  MDR-*A*. *baumannii* (22/24)                                  91.7%            0.001     \[[@pone.0189621.ref041]\]

  Susceptible *A*. *baumannii* (12/25)                               48%                                                                                                           

  Amer et al. (2015)                                                 Emergency\           CR-MBLP-*P*. *aeruginosa* (14/32)                             43,8%            0.2       \[[@pone.0189621.ref064]\]
                                                                     ICU /Pediatric ICU                                                                                            

  CR-MBLN-*P*. *aeruginosa* (2/8)                                    25%                                                                                                           

  Furtado et al. (2009)                                              ICU                  Imipenem-resistant *P*. *aeruginosa* (31/63)                  49%              0.02      \[[@pone.0189621.ref031]\]

  Imipenem-susceptible *P*. *aeruginosa* (61/182)                    33%                                                                                                           

  Marra et al. (2006)                                                ICU                  ESBL-producing *K*. *pneumoniae* (18/56)                      32.14%           0.042     \[[@pone.0189621.ref046]\]

  Non-ESBL *K*. *pneumoniae* (8/52)                                  15.38%                                                                                                        

  Moreira et al. (2008)                                              ICU                  ORSA (11/29)                                                  37.9%            0.41      \[[@pone.0189621.ref047]\]

  OSSA (8/32)                                                        25%                                                                                                           

  Serefhanoglu et al. (2009)                                         ICU                  MDR-ESBL-producing-*E*. *coli* and *K*. *pneumoniae* (7/30)   23.3%            0.606     \[[@pone.0189621.ref032]\]

  Non-MDR-ESBL-producing-*E*. *coli* and *K*. *pneumoniae* (12/64)   18.8%                                                                                                         

  Tuon et al. (2012)                                                 ICU                  Carbapenem-resistant *P*. *aeruginosa* (13/29)                54.2%            0.043     \[[@pone.0189621.ref022]\]

  Carbapenem-susceptible *P*. *aeruginosa* (26/48)                   44.8%                                                                                                         

  Chen et al. (2012)                                                 ICU                  MRSA (25/75)                                                  33%              0.01      \[[@pone.0189621.ref048]\]

  MSSA (8/43)                                                        18.6%                                                                                                         

  Fu et al. (2015)                                                   ICU                  XDR *A*. *baumannii* (31/39)                                  79.5%            0.1       \[[@pone.0189621.ref049]\]

  Non-XDR *A*. *baumannii* (38/86)                                   44.2%                                                                                                         

  Jia et al. (2015)                                                  ICU                  Linezolid non-susceptible Enterococci (3/44)                  6.8%             0.521     \[[@pone.0189621.ref050]\]

  Linezolid-susceptible Enterococci (2/44)                           4.5%                                                                                                          

  Un-infected Control patients (3/176)                               1.7%                                                                                                          

  Yao et al. (2015)                                                  ICU                  MRSA (12/57)                                                  21%              0.002     \[[@pone.0189621.ref035]\]

  MSSA (9/116)                                                       8%                                                                                                            

  Gomez Rueda et al. (2014)                                          ICU                  Carbapenem resistant *K*. *pneumoniae* (31/61)                50.8%            0.042     \[[@pone.0189621.ref036]\]

  Carbapenem-susceptible *K*. *pneumoniae* (20/61)                   32.7%                                                                                                         

  Un-infected control patients (25/122)                              20.4%                                                                                                         

  Kumar et al. (2014)                                                ICU                  Carbapenem-resistant *A*. *baumannii* (9/33)                  27.3%            0.074     \[[@pone.0189621.ref037]\]

  Carbapenem-susceptible *A*. *baumannii* (3/32)                     9.4%                                                                                                          

  Nazer et al. (2015)                                                ICU                  MDR-*A*. *baumannii* (118/161)                                73.3%            0.015     \[[@pone.0189621.ref053]\]

  Non-MDR-*A*. *baumannii* (142/232)                                 61.2%                                                                                                         

  Deris et al. (2011)                                                ICU                  Imipenem-resistant -*A*. *baumannii* (6/15)                   42.9%            0.201     \[[@pone.0189621.ref039]\]

  Imipenem-susceptible *A*. *baumannii* (9/41)                       24.3%                                                                                                         

  Inchai et al. (2015)                                               ICU                  MDR-*A*. *baumannii* (10/72)                                  13.9%            0.001     \[[@pone.0189621.ref044]\]

  XDR- *A*. *baumannii* (88/220)                                     40%                                                                                                           

  PDR*-A*. *baumannii* (7/12)                                        58.3%                                                                                                         

  Jamulitrat et al. (2009)                                           ICU                  Imipenem-resistant-*A*. *baumannii* (35/67)                   52.2%            0.001     \[[@pone.0189621.ref059]\]

  Imipenem-susceptible *A*. *baumannii* (26/131)                     19.9%%                                                                                                        

  Thatrimontrichai et al. (2016)                                     ICU                  Carbapenem-resistant *A*. *baumannii* (10/63)                 15.9%            0.01      \[[@pone.0189621.ref019]\]

  Carbapenem-susceptible *A*. *baumannii* (1/13)                     7.7%                                                                                                          

  Un-infected control patients (0/25)                                0%                                                                                                            

  Topeli et al. (2000)                                               ICU                  MRSA (15/46)                                                  32.6%            0.02      \[[@pone.0189621.ref021]\]

  MSSA (7/55)                                                        12.7%                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CR: Carbapenem-resistant; CS: Carbapenem susceptible; MBL: Metallo-beta-lactamase; IS: imipenem sensitive; IR: imipenem resistant; ICU: Intensive Care Unit; OSSA: Oxacillin-sensitive-*S*. *aureus;* ORSA: Oxacillin-resistant-*S*. *aureus*; PDR: Pan drug resistant; XDR: Extensive drug resistant

Statistical analysis {#sec015}
--------------------

### Primary analyses {#sec016}

Pooled estimates revealed 90% prevalence (95%CI, 2.852--3.557; p = 0.000) of mortality attributable to infections in developing countries with greater mortality associated with ABR at an odds ratio (OR) 2.828 (95%CI, 2.231--3.584; p = 0.000) ([Fig 3A](#pone.0189621.g003){ref-type="fig"}).

![Forest plot of impact of ABR on mortality and sub-group analyses per World Bank classification, WHO regions, countries, group of bacteria and bacteria species.\
3A. Forest plot of overall impact of antibiotic-resistance on mortality in included studies. 3B. Forest plot of impact of ABR on mortality analyzed per World Bank Classification. 3C. Forest plot of impact of ABR on mortality analyzed per WHO regions. 3D. Forest plot of impact of ABR on mortality analyzed per countries. 3E. Forest plot of impact of AMR on mortality analyzed per group of bacteria. 3F. Forest plot of impact of ABR on mortality analyzed per bacterial species.](pone.0189621.g003){#pone.0189621.g003}

### Subgroup analyses {#sec017}

The subgroup analyses were performed by World Bank classification, WHO region, country, group of bacteria and bacterial species. [Fig 3B](#pone.0189621.g003){ref-type="fig"} presents a forest plot of mortality due to AMR categorized per World Bank classification. The risk of mortality due to resistant bacteria was high in upper middle-income countries (OR 2.769, 95% CIs, 2.142--3.579; p = 0.000), with studies from lower-middle and low-income nations not being evaluated due to insufficient data.

Four out of the six WHO regions were included in the analysis, with three showing a high risk of mortality ([Fig 3C](#pone.0189621.g003){ref-type="fig"}). High statistical significance was observed in the Americas (OR 2.126, 95% CIs; 1.546--2.925; p = 0.000), South East Asia (OR 3.754, 95% CIs; 2.333--6.041; p = 0.000) and the Western Pacific (OR 3.746, 95% CIs; 2.463--5.697; p = 0.000) ([Fig 3C](#pone.0189621.g003){ref-type="fig"}). Results from Europe were not statistically significant and insufficient reports precluded analysis in Africa.

Subgroup analyses per country showed high statistical significance (OR 2.665, 95%CIs; 2.074--3.425, p = 0.000) ([Fig 3D](#pone.0189621.g003){ref-type="fig"}) in favor of mortality. Brazil, China and Thailand, had statistically significant risk of mortality with OR being 1.825 (95%CIs; 1.239--2.689; p = 0.002), 3.746 (95%CIs; 2.463--5.697; p = 0.000), 3.928 (95%CIs; 2.116--7.293; p = 0.000) respectively, in contrast to Turkey, which was not statistically significant ([Fig 3D](#pone.0189621.g003){ref-type="fig"}). In other countries, the number of reports was insufficient (less than three) to perform the meta-analysis.

Studies were categorized into three groups of bacteria namely ESKAPE, non-ESKAPE, and mixed (both ESKAPE and non-ESKAPE). The ESKAPE group was associated with the highest risk of mortality with a high statistical significance (OR 3.217; 95%CIs; 2.395--4.321; p = 0.001) ([Fig 3E](#pone.0189621.g003){ref-type="fig"}). Although, the non-ESKAPE group was not associated with the risk of mortality (OR 1.167; 95%CIs; 0.385--3.534; p = 0.000), when combined with ESKAPE within a study, it became statistically significant (OR 2.634; 95%CIs; 1.858--3.734; p = 0.000) ([Fig 3E](#pone.0189621.g003){ref-type="fig"}).

High risk of mortality due to antibiotic-resistant *A*. *baumannii* was observed with high statistical significance (OR 4.636; 95%CIs; 2.954--7.277; p = 0.000), followed by *S*. *aureus* (OR 2.842; 95%CIs; 1.868--4.324; p = 0.000). *P*. *aeruginosa* (OR 2.076; 95%CIs; 0.833--5.177; p = 0.117) and *K*. *pneumoniae* (OR 2.026; 95%CIs; 0.733--5.598; p = 0.173) were not significantly associated with mortality ([Fig 3F](#pone.0189621.g003){ref-type="fig"}).

Discussion {#sec018}
==========

AMR is a global public health threat that affects human health, particularly hospitalized patients, and has substantive health and financial consequences. This study analyzed the published literature on the clinical and economic implications of ABR in developing countries from 40 eligible studies. Antibiotic-resistant bacteria were associated with increased mortality (OR 2.8341, 95%CIs; 2.2180--3.6213; P = 0.000), consistent with several reports in both developed and developing countries \[[@pone.0189621.ref066]--[@pone.0189621.ref069]\]. The main ward involved was the ICU, possibly due to the heavy use of antibiotics and hence the selection pressure for ABR development and prevalence in these units \[[@pone.0189621.ref004], [@pone.0189621.ref023], [@pone.0189621.ref070], [@pone.0189621.ref071]\]). This concurred with studies from Mexico, Brazil, China, Thailand, France and Serbia, that reported high mortality due to antibiotic-resistant bacteria in ICUs \[[@pone.0189621.ref017], [@pone.0189621.ref049], [@pone.0189621.ref067], [@pone.0189621.ref071]--[@pone.0189621.ref073]\]. The study further showed that ABR research is neglected in developing countries with only one report from low-income (Senegal), two from lower-income (Palestine and Jordan), and 37 from upper-middle income nations ([Table 1](#pone.0189621.t001){ref-type="table"} and [Fig 2](#pone.0189621.g002){ref-type="fig"}). Developing countries are thus far behind high resource settings in the fight against AMR and that requiring considerable efforts to reduce its consequences \[[@pone.0189621.ref074]\]. Three WHO regions, i.e., the Americas, South East Asia and the Western Pacific region showed the highest risk of mortality associated with MRSA and *K*. *pneumoniae* resistant to third generation cephalosporins. Our results concurred with the 2014's WHO report, which showed a significant increase of mortality due to antibiotic-resistant *K*. *pneumoniae* and *S*. *aureus* in hospitals particularly in ICU across WHO regions \[[@pone.0189621.ref002]\]. Resistance levels could be explained by the practices of self-medication and the purchase of antibiotics over-the-counter common in these settings. Policies and regulations promoting rational antibiotic use are also minimal or non-existent. Additionally, limitations in managing nosocomial infections, sub-optimal infection control measures, unsafe water, poor hygienic conditions, lack of knowledge and inadequately trained personnel might also be associated with the prevailing resistance in these regions. Comprehensive studies are needed to provide accurate and reliable data to inform decision-makers about the danger of ABR in developing countries and suggest a way forward for the alleviation of the resulting implications.

Resistant ESKAPE bacteria including carbapenem-resistant *A*. *baumannii*, MBL- producing *P*. *aeruginosa*, ESBL-producing *K*. *pneumoniae*, and MRSA represented the most common resistant bacteria associated with increased mortality. These bacteria were the main cause of morbidity and mortality in bloodstream infections in hospital settings, with a high statistical significance (OR 2.978, 95%CIs; 2.362--3.753; p = 0.000) ([Fig 3F](#pone.0189621.g003){ref-type="fig"}). This concurred with the WHO Global Antimicrobial Surveillance System (GLASS), which recognized *A*. *baumannii*, *K*. *pneumoniae*, and *S*. *aureus*, as priority pathogens in blood specimens and list them together with *P*. *aeruginosa* as priority antibiotic resistant-bacteria for research and development in 2017 \[[@pone.0189621.ref004], [@pone.0189621.ref005]\].

According to the meta-analysis, MDR-ESKAPE were associated with a greater risk of mortality than mono-drug (including imipenem, methicillin, and linezolid) resistant bacteria, with a high statistical significance (OR 2.846, 95% CIs; 1.744--4.643; p = 0.000; versus OR 2.301; 95%CIs; 1.718--3.082; p = 0.000; [Table 3](#pone.0189621.t003){ref-type="table"}). Moreover, when comparing the mortality risk between resistant- and susceptible-ESKAPE pathogens ([Table 3](#pone.0189621.t003){ref-type="table"}), results showed that carbapenem-resistant *A*. *baumannii* (CRAB) were associated with higher mortality risk than susceptible strains with a high statistical significance \[[@pone.0189621.ref002], [@pone.0189621.ref005]\]. The pooled estimate of mortality rate ranged from 15.9 to 91.7% (p = 0.001), consistent with a report from Taiwan, where a significant increase of mortality from 14% to 46% (p = 0.0001) was associated with carbapenem-resistant-*A*. *baumannii* implicated in HAIs during 2003--2008 \[[@pone.0189621.ref075]\].

Although the mortality attributable to ESKAPE pathogens is indisputable compared to non-ESKAPE pathogens, we observed that when these two groups infected patients concomitantly, they were associated with a long length of hospital stay (LOS) and a higher mortality. This concurred with studies from Senegal \[[@pone.0189621.ref055]\], Turkey \[[@pone.0189621.ref003]\] and China \[[@pone.0189621.ref035], [@pone.0189621.ref050]\] which have reported high LOS and death due to MDR-*A*. *baumannii*, ESBL-producing *Enterobacteriaceae* and MRSA, respectively.

Eight studies reported that ABR increased health care costs with resistant ESKAPE bacteria being the main causative agents associated with high hospital costs ([Table 4](#pone.0189621.t004){ref-type="table"}). Four out of the eight revealed that length of stay had an impact on hospital costs. LOS was also a risk factor for acquisition of nosocomial infections, and thereby increased mortality. Overall, health-care costs in all studies for case and control groups were 8,107.375 USD versus 5,469.487 USD respectively. Two studies indicated health care costs \>10 000 USD in Thailand and Colombia \[[@pone.0189621.ref019], [@pone.0189621.ref051]\] while one report showed cost ≥ 35 000 USD in Turkey \[[@pone.0189621.ref003]\]. In contrast, three studies reported overall hospital costs ≤ 1000 USD \[[@pone.0189621.ref055]--[@pone.0189621.ref057]\], with one below 250 USD in Senegal \[[@pone.0189621.ref055]\]. These differences are attributed to the diverse socio-economic characteristics of the countries concerned.

10.1371/journal.pone.0189621.t004

###### Summary of data on health care costs associated with resistant infections.

![](pone.0189621.t004){#pone.0189621.t004g}

  Country    WHO Region                World Bank classification   Settings              Follow-up period   Overall Health care costs   References                
  ---------- ------------------------- --------------------------- --------------------- ------------------ --------------------------- ------------- ----------- ----------------------------
  Colombia   Americas (PAHO)           Upper Middle Income         Tertiary hospital     30 days            11 822 USD                  7 178 USD     \< 0.001    \[[@pone.0189621.ref051]\]
  India      South East Asia (SEARO)   Upper middle income         Tertiary hospital     NR                 1 478 USD                   790 USD       \< 0.001    \[[@pone.0189621.ref052]\]
  Senegal    Africa (AFRO)             Low income                  Hospital              NR                 228 USD                     122 USD       \< 0.0001   \[[@pone.0189621.ref055]\]
  Thailand   South East Asia (SEARO)   Upper middle income         University Hospital   34 days            935 USD                     122 USD       \< 0.05     \[[@pone.0189621.ref056]\]
  Thailand   South East Asia (SEARO)   Upper middle income         University Hospital   43 days            615 USD                     214 USD       \< 0.05     \[[@pone.0189621.ref057]\]
  Thailand   South East Asia (SEARO)   Upper middle income         University Hospital   NR                 2731 USD                    1 199 USD     \< 0.001    \[[@pone.0189621.ref058]\]
  Thailand   South East Asia (SEARO)   Upper middle income         University Hospital   NR                 11 773 USD                  7 797.9 USD   \< 0.05     \[[@pone.0189621.ref019]\]
  Turkey     Europe(EURO)              Upper middle income         University Hospital   28 days            35 277 USD                  26 333 USD    \< 0.282    \[[@pone.0189621.ref003]\]

In terms of the limitations of the study, several papers were not included in the meta-analysis because they did not provide sufficient information regarding clinical and/or economic impact of ABR in developing countries. We were unable to present the genomic characteristics of antibiotic-resistant bacteria due to the scarcity of data. In addition, we did not focus on antibiotic classes and resistance patterns due to the lack of standard methods for identification and interpretation in developing countries. Moderate heterogeneity (*I*^*2*^ *=* 58.88%, *p =* 0.000) was reported, which could be due to various external factors, such as different type of studies (retrospective, retrospective cohort, retrospective case-control, prospective cohort, prospective case-control, etc.), diverse populations (adult, children, neonates), infection prevention and control measures and antimicrobial stewardship practices. Moreover, minor publication bias was observed in the funnel plot ([Fig 4](#pone.0189621.g004){ref-type="fig"}) which could possibly be attributed to the lack of reports from lower-middle and low-income countries. We tried to limit the influence of heterogeneity and publication bias in our statistical analysis by using the random effects model that considers differences within and between studies, as well as by including articles in different languages (English and French).

![Funnel plot of standard error by log odds ratio.](pone.0189621.g004){#pone.0189621.g004}

Conclusion and recommendations {#sec019}
==============================

The key findings of this study confirm that ABR, particularly antibiotic-resistant ESKAPE pathogens are associated with a high risk of mortality and greater economic costs. Developing countries need to optimize their management of communicable and non-communicable diseases, implement infection, prevention and control (IPC) measures, as well as antimicrobial stewardship programs (ASP) in both hospital and community settings to reduce morbidity, mortality and the costs associated with ABR. Furthermore, optimization of rational antibiotic use at regional and national levels, is essential to ensure a high quality and effective of therapeutic options \[[@pone.0189621.ref076]\]. Substantial and sustainable efforts to develop rapid diagnostics, new antibiotics and vaccines are required. An international platform for global real-time surveillance and monitoring of antimicrobial resistance could advance containment of this threat.
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